Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Receivables (2016 - 2019)

Theravance Biopharma (TBPH) has disclosed Receivables for 7 consecutive years, with $20.1 million as the latest value for Q3 2019.

  • Quarterly Receivables rose 189.81% to $20.1 million in Q3 2019 from the year-ago period, while the trailing twelve-month figure was $20.1 million through Sep 2019, up 189.81% year-over-year, with the annual reading at $6.0 million for FY2018, 35.46% down from the prior year.
  • Receivables for Q3 2019 was $20.1 million at Theravance Biopharma, roughly flat from $20.1 million in the prior quarter.
  • The five-year high for Receivables was $39.1 million in Q1 2016, with the low at $4.8 million in Q1 2018.
  • Average Receivables over 5 years is $17.1 million, with a median of $13.1 million recorded in 2017.
  • The sharpest move saw Receivables skyrocketed 674066.67% in 2015, then crashed 81.96% in 2017.
  • Over 5 years, Receivables stood at $37.2 million in 2015, then tumbled by 73.83% to $9.7 million in 2016, then decreased by 3.7% to $9.4 million in 2017, then crashed by 35.46% to $6.0 million in 2018, then soared by 232.46% to $20.1 million in 2019.
  • According to Business Quant data, Receivables over the past three periods came in at $20.1 million, $20.1 million, and $7.9 million for Q3 2019, Q2 2019, and Q1 2019 respectively.